Major Depressive Disorder

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, share their approach to treatment-resistant depression.

Drs Andrew J. Cutler, Gregory Mattingly, and Sagar V. Parikh discuss the treatment of MDD in female patients who are pregnant or plan to become pregnant.

The same risk was not found for offspring of fathers with primary immunodeficiencies.

Experts in psychiatry review factors to consider when deciding to switch or augment treatment in major depressive disorder [MDD].

Drs Andrew J Cutler, Gregory Mattingly, and Sagar V Parikh provide advice to clinicians on monitoring treatment in major depressive disorder.

Experts in psychiatry provide insight into treating episodic vs chronic major depressive disorder and factors they consider when approaching treatment selection.

Andrew J Cutler, MD; Gregory Mattingly, MD; and Sagar V Parikh, MD, FRCPC, discuss clinical data on zuranolone from the WATERFALL, CORAL, and SHORELINE studies for the treatment of major depressive disorder.

Personality disorders, adjustment disorder, bipolar disorder, insomnia, and anxiety disorders were risk factors associated with postpartum depression.

Use of Zuranolone for Treatment of MDD

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, review newly approved additions to the major depressive disorder treatment landscape, including esketamine, brexanolone, AXS-05 (dextromethorphan/bupropion).

Experts in psychiatry discuss unmet needs in the treatment of major depressive disorder and how new agents are aiming to fulfill these needs.

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, comment on the limitations and challenges of traditional treatments for MDD, such as length of treatment and adverse events.

Patients with late-onset depression died on average 1 year earlier than those with early-onset depression or those without late-life depression.

A new cross-sectional analysis suggest there are few options available for patients with schizophrenia or a serious mood disorder.

Sagar V. Parikh, MD, FRCPC, reviews factors that lead to the use of antidepressants in the treatment of MDD.

Gregory Mattingly, MD, provides an overview of currently available treatment options for MDD.

Neither finasteride nor dutasteride were linked to an increased risk of suicide.

Sagar V. Parikh, MD, FRCPC, leads a discussion on patient engagement and shared decision-making in treatment selection in MDD.

Drs Andrew J. Cutler, Gregory Mattingly, and Sagar V. Parikh share their approach to treatment selection for patients with MDD.

Serotonin syndrome occurred in less than 0.5% of patients, while the number of serotonin syndrome cases was fewer in the antidepressant group.

TRD episodes resulted in more inpatient bed-days and lost workdays compared to non-TRD episodes.

The indication expands the marketed use of the atypical antipsychotic drug to be used with antidepressants in adult patients.

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, discuss the connection between depression and other health conditions, as well as the economic impact of major depressive disorder [MDD].

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, review trends in the prevalence of major depressive disorder (MDD) in the US, and the impact of the COVID-19 pandemic on MDD trends.

New phase 2 data show a synthetic, proprietary 25 mg dose from COMPASS may fare better for adult patients than a 10 mg dose.